• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Denmark·Basic Materials·NVZMY
Share

Novozymes A/S Stocks

$ 67.65Last Updated 13.11.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

$ 31.14B

$ 67.65
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Weak margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Novozymes A/S is a global biotechnology firm that specializes in the creation and distribution of industrial enzymes, microorganisms, and probiotics. Its operational footprint spans across Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific region. The company's broad range of products caters to numerous sectors: Food and Beverages: Supplying ingredients and processing aids for baking, a variety of beverages, dairy production, starch modification, and protein applications. Household Care: Delivering specialized formulations for laundry, dishwashing, and professional cleaning solutions. Agriculture: Providing innovations for crop cultivation, animal health and nutrition, alongside bioyield and biocontrol products for plant growth. Bioenergy and Industrial Processing: Offering critical components for grain and technical processing, encompassing liquefaction, saccharification, fermentation, fiber conversion, and biomass transformation. Textiles: Featuring technologies for biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing. Pulp and Paper: Enhancing processes through fiber modification, bleach boosting, deposit control, starch modification, and deinking agents. Leather Production: Furnishing treatments for acid bating, area expansion, general bating, degreasing, soaking, and unhairing/liming stages. Water and Waste Management: Contributing with bioaugmentation strategies, optimization of biogas production, and sludge management. Pharmaceuticals: Supplying specialized lipases (both free and immobilized), proteases for biocatalysis, and rTrypsin vital for cell culture applications. Furthermore, Novozymes provides offerings related to human health and various protein-based products. Founded in 1925, Novozymes A/S is headquartered in Bagsvaerd, Denmark.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair value on

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of NVZMY is 77.1 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.11.2026 13:01

Is There Life After Huang? The Rise of Anthropic, and the AI Rally in the Clouds

14.11.2026 04:56

Key Starship tests did not go as planned. SpaceX shares fell

14.11.2026 04:35

The S&P 500 posted its best week in six months. Barclays expects growth for the first time since March

14.11.2026 03:40

Huang still holds $135 billion worth of Nvidia stock. Why is this worrying investors?

14.11.2026 02:56

Nvidia's Worst Week: A $570 Billion Loss and the Most Cautious Analysts in 3 Years

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026